Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR
(2026) Rhinology Journal — Vol. 64, n° 3, p. 420-422 (2026)
Files
Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis nasal polyps CRSwNP findings from CHRINOSOR.pdf
Open Access - Adobe PDF
- 2.68 MB
Details
- Authors
- et. al.
- Abstract
- Omalizumab is a recombinant DNA-derived humanized monoclonal antibody targeting free immunoglobulin E. In the omalizumab phase III studies for chronic rhinosinusitis with nasal polyp (CRSwNP), a clinically relevant reduction of the nasal polyp score (NPS) was observed leading to improved SinoNasal Outcome Test-22 (SNOT-22) (1). In the extension study, sustained or further improvement of symptoms and NPS reduction were observed up to 52 weeks (2). Real-world data is needed to establish effectiveness in uncontrolled severe CRSwNP (3), but so far, data on long-term omalizumab treatment is sparse (4,5).
- Affiliations
Citations
Bartosik, T., Seys, S., De Kinderen, J., Wagenmann, M., Bruch, M., Andrianakis, A., Gonzalez-Compta, X., Hox, V., Pardo Muñoz, L., Schneider, S., Bettio, G., Burian, M., Eckl-Dorna, J., Golet Fors, M., Mariën, G., Morgenstern, C., Scheckenbach, K., Tomazic, P.-V., Tu, A., et al. (2026). Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR. Rhinology Journal, 64(3), 420-422. https://doi.org/10.4193/rhin25.514 (Original work published 2026)